Tianjin Kind Pharma Co., Ltd.
Assessed Supplier Enterprise Certification
- Assessed
Supplier - 1st
years
Assessed Supplier Enterprise Certification
Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
Tel: +86-15510908448
Mobile: +86-15510908448
Tel: +86-15510908448
Fax: +86-15510908448
URL: http://www.kindpharma.biz
Province/state: Tianjin
City: Tianjin
Street: No.22 Quanwang Road, Wuqing Development Zone, Tianjin, China
MaxCard:
Contact Suppliers
CAS NO.131918-61-1
Quality Manufacturer Supply Best Quality 131918-61-1 On Stock, accept customization.
Paricalcitol is a synthetic vitamin D2 agonist used to treat hyperparathyroidism associated with stage 3 or greater chronic kidney disease. It is approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD). Hyperparathyroidism occurs when the parathyroid glands, located in the neck, produce an excess of parathyroid hormone (PTH).
In clinical studies, paricalcitol has been shown to effectively reduce PTH concentrations without causing significant hypercalcemia or hyperphosphatemia when compared to placebo. The treatment reduces PTH concentrations more rapidly with fewer sustained episodes of hypercalcemia and increased calcium-phosphorus product compared to calcitriol therapy. Paricalcitol's effect on reducing proteinuria has been examined in patients with detectable proteinuria at baseline. The reduction in proteinuria is of interest due to its association with renal and cardiovascular protection. Further investigation in randomized, controlled trials using quantitative assays for albumin excretion is warranted.
Paricalcitol is administered orally, with or without food, as directed by a doctor. The frequency of administration may vary, with the medication typically taken once daily or three times a week. The dosage is based on the patient's condition, weight, lab tests, and response to treatment. Paricalcitol is available in various strengths and formulations. It comes in single-dose vials with concentrations of 2 mcg/mL or 5 mcg/mL and multiple-dose vials with a concentration of 10 mcg/2 mL (5 mcg/mL).
For some patients, paricalcitol is administered intravenously during dialysis sessions. The injection is typically given three times a week, every other day, and the dosage is based on the patient's condition. It is important to consult a doctor regarding the use of paricalcitol during pregnancy.